mTOR: An attractive therapeutic target for osteosarcoma?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Osteosarcoma (OS) is a prevalent bone cancer in young individuals, characterized by poor prognosis and chemotherapy resistance.
• The mammalian target of rapamycin (mTOR) pathway is frequently activated in OS, promoting tumor growth and metastasis.

Purpose of the Study:

• To review the role of the mTOR pathway in osteosarcoma.
• To summarize the current research on mTOR inhibitors for OS treatment.
• To explore combination therapies involving mTOR inhibitors for improved OS management.

Main Methods:

• Literature review of studies on mTOR signaling in osteosarcoma.
• Analysis of preclinical and clinical research on mTOR inhibitors in OS.
• Discussion of potential combination strategies with mTOR inhibitors.

Main Results:

• mTOR pathway activation is a key driver of OS progression.
• mTOR inhibitors demonstrate potential as targeted therapies for OS.
• Combination therapies may overcome resistance and enhance treatment efficacy.

Conclusions:

• Targeting the mTOR pathway represents a promising therapeutic strategy for osteosarcoma.
• Further research into mTOR inhibitors and combination therapies is warranted to improve patient outcomes.